These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196 [TBL] [Abstract][Full Text] [Related]
5. Tech: a RhoA GEF selectively expressed in hippocampal and cortical neurons. Marx R; Henderson J; Wang J; Baraban JM J Neurochem; 2005 Feb; 92(4):850-8. PubMed ID: 15686487 [TBL] [Abstract][Full Text] [Related]
6. Actin dynamics control SRF activity by regulation of its coactivator MAL. Miralles F; Posern G; Zaromytidou AI; Treisman R Cell; 2003 May; 113(3):329-42. PubMed ID: 12732141 [TBL] [Abstract][Full Text] [Related]
7. Muscle-specific signaling mechanism that links actin dynamics to serum response factor. Kuwahara K; Barrientos T; Pipes GC; Li S; Olson EN Mol Cell Biol; 2005 Apr; 25(8):3173-81. PubMed ID: 15798203 [TBL] [Abstract][Full Text] [Related]
8. Mutant actins that stabilise F-actin use distinct mechanisms to activate the SRF coactivator MAL. Posern G; Miralles F; Guettler S; Treisman R EMBO J; 2004 Oct; 23(20):3973-83. PubMed ID: 15385960 [TBL] [Abstract][Full Text] [Related]
9. OTT-MAL is a deregulated activator of serum response factor-dependent gene expression. Descot A; Rex-Haffner M; Courtois G; Bluteau D; Menssen A; Mercher T; Bernard OA; Treisman R; Posern G Mol Cell Biol; 2008 Oct; 28(20):6171-81. PubMed ID: 18710951 [TBL] [Abstract][Full Text] [Related]
10. Induction of megakaryocyte differentiation drives nuclear accumulation and transcriptional function of MKL1 via actin polymerization and RhoA activation. Smith EC; Teixeira AM; Chen RC; Wang L; Gao Y; Hahn KL; Krause DS Blood; 2013 Feb; 121(7):1094-101. PubMed ID: 23243284 [TBL] [Abstract][Full Text] [Related]
11. Developmental expression of the SRF co-activator MAL in brain: role in regulating dendritic morphology. Shiota J; Ishikawa M; Sakagami H; Tsuda M; Baraban JM; Tabuchi A J Neurochem; 2006 Sep; 98(6):1778-88. PubMed ID: 16945101 [TBL] [Abstract][Full Text] [Related]
12. The SRF target gene Fhl2 antagonizes RhoA/MAL-dependent activation of SRF. Philippar U; Schratt G; Dieterich C; Müller JM; Galgóczy P; Engel FB; Keating MT; Gertler F; Schüle R; Vingron M; Nordheim A Mol Cell; 2004 Dec; 16(6):867-80. PubMed ID: 15610731 [TBL] [Abstract][Full Text] [Related]
13. The RhoA effector mDiaphanous regulates MyoD expression and cell cycle progression via SRF-dependent and SRF-independent pathways. Gopinath SD; Narumiya S; Dhawan J J Cell Sci; 2007 Sep; 120(Pt 17):3086-98. PubMed ID: 17684061 [TBL] [Abstract][Full Text] [Related]
14. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β-induced fibrogenesis in human colonic myofibroblasts. Johnson LA; Rodansky ES; Haak AJ; Larsen SD; Neubig RR; Higgins PD Inflamm Bowel Dis; 2014 Jan; 20(1):154-65. PubMed ID: 24280883 [TBL] [Abstract][Full Text] [Related]
15. Role of megakaryoblastic acute leukemia-1 in ERK1/2-dependent stimulation of serum response factor-driven transcription by BDNF or increased synaptic activity. Kalita K; Kharebava G; Zheng JJ; Hetman M J Neurosci; 2006 Sep; 26(39):10020-32. PubMed ID: 17005865 [TBL] [Abstract][Full Text] [Related]
16. Transcriptional activity of megakaryoblastic leukemia 1 (MKL1) is repressed by SUMO modification. Nakagawa K; Kuzumaki N Genes Cells; 2005 Aug; 10(8):835-50. PubMed ID: 16098147 [TBL] [Abstract][Full Text] [Related]
17. MAL and ternary complex factor use different mechanisms to contact a common surface on the serum response factor DNA-binding domain. Zaromytidou AI; Miralles F; Treisman R Mol Cell Biol; 2006 Jun; 26(11):4134-48. PubMed ID: 16705166 [TBL] [Abstract][Full Text] [Related]
18. Serum response factor activation by muscarinic receptors via RhoA. Novel pathway specific to M1 subtype involving calmodulin, calcineurin, and Pyk2. Lin K; Wang D; Sadée W J Biol Chem; 2002 Oct; 277(43):40789-98. PubMed ID: 12200418 [TBL] [Abstract][Full Text] [Related]
19. MAL/SRF complex is involved in platelet formation and megakaryocyte migration by regulating MYL9 (MLC2) and MMP9. Gilles L; Bluteau D; Boukour S; Chang Y; Zhang Y; Robert T; Dessen P; Debili N; Bernard OA; Vainchenker W; Raslova H Blood; 2009 Nov; 114(19):4221-32. PubMed ID: 19724058 [TBL] [Abstract][Full Text] [Related]
20. Megakaryoblastic leukemia-1/2, a transcriptional co-activator of serum response factor, is required for skeletal myogenic differentiation. Selvaraj A; Prywes R J Biol Chem; 2003 Oct; 278(43):41977-87. PubMed ID: 14565952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]